This immune checkpoint assay is designed to identify human CD47/SIRP alpha inhibitors.

See more
  • All inclusive kit All inclusive kit
  • Scalable from 96 to 1536 format Scalable from 96 to 1536 format
  • Validated with reference Ab Validated with reference Ab

This immune checkpoint assay is designed to identify human CD47/SIRP alpha inhibitors.

In stock


Signal-regulatory protein alpha (SIRP-alpha), also known as CD172a, is a cell surface protein expressed mainly by myeloid cells, such as macrophages. Its receptor, CD47, is ubiquitously expressed on the surface of all cells and has been found to be overexpressed in some cancers. CD47 binding to SIRP-alpha delivers a "Do Not Eat Me" signal to macrophages. In the case of a tumor, this signaling aids in tumor evasion of the immune system. Inhibitors of this interaction hold great promise for cancer immunotherapy.



Assay principle

The CD47/SIRP binding assay includes human recombinant immune checkpoint partners tagged for detection (CD47 and SIRP alpha) and labelled anti-tag reagents for HTRF detection. Without an inhibitor, CD47 binds to SIRP alpha, and the binding of each detection reagent to its tagged target generates an HTRF signal. In the presence of compound, standard or an antibody blocking the CD47/SIRP alpha interaction, the HTRF signal decreases.

HTRF human CD47/SIRPα binding kit assay principal

Assay protocol

 This CD47/SIRP alpha binding assay can be run in a 96- or 384-well low volume white plate (20 µL final). As described here, samples or standards are dispensed directly into the assay plate, and the tagged CD47 & SIRP alpha protein are then added, followed by the dispensing of the HTRF reagents. The reagents labelled with HTRF fluorophores may be pre-mixed and added in a single dispensing step. No washing steps are needed. The protocol can be further miniaturized or upscaled by simply resizing each addition volume proportionally.

HTRF human CD47/SIRPα binding kit assay protocol

Inhibitory effect of the blocking standard

Performing an 8-point dose response curve using the blocking standard provided in the kit. The CD47-SIRP alpha interaction is inhibited, with an IC50 of 2.6 nM.

Inhibitory effect of the blocking standard

Inhibitory effect of blocking antibodies

The inhibitory effects of three antibodies known to inhibit the CD47-SIRP alpha interaction were tested. The two anti-CD47 antibodies (B6H12 & B6H12.2) were shown to inhibit the interaction, with IC50s of 2.2 & 1.6 nM respectively. The anti-SIRP alpha antibody (SE5A5) disrupted the interaction, with an IC50 of 2.4 nM.

Inhibitory effect of blocking antibodies

Best practices for pharmacological characterization of PPI inhibitors

Easy pharmacological characterization of PPI modulators. - Technical Notes

HTRF assays handle low- to high affinity protein-protein interactions

Deciphering low- and high affinity interactions - Application Notes

Nuclear receptor ligand identification with HTRF

Monitoring nuclear receptor binding with HTRF assays - Application Notes

HTRF addresses large protein-protein interaction complexes

Challenge large complexes with HTRF assays - Application Notes

HTRF PPI your dream assay served on a plate

Sandwiches aren't just for eating - Infographics

A brief history of Protein-Protein Interactions

How well do you know PPI? - Infographics

Cisbio Product Catalog 2019

All your HTRF assays in one document! - Catalog

A guide to Homogeneous Time Resolved Fluorescence

General principles of HTRF - Guides

How HTRF compares to Western Blot and ELISA

Get the brochure about technology comparison. - Brochures

Virology research solutions using HTRF Protein-Protein Interaction assays

See how peer researchers challenge the viral life cycle with PPI assays - Application Notes